LMO4

Across TCGA pan-cancer cohorts, LMO4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LMO4 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LMO4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated LMO4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where LMO4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.789	0.412	<.001	43	view →
CCRCC	OS	Median	All	0.872	1.000	.002	29	view →
UCEC	DFS	Tertile	All	0.790	0.950	.039	4	view →
LSCC	DFS	Median	III,IV	0.938	0.667	.034	1	view →
LUAD	DFS	Quartile	All	0.874	0.945	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LMO4–PDAC (OS)

Open the PDAC breakdown →